Deferasirox in MDS patients with transfusion-caused iron overload—a phase-II study

World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues

D. K. Hossfeld · Annals of Oncology · 2002 · 4.6K citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Tumoral Pathology +11

MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients

John C. Wood, Cathleen Enriquez, Nilesh R. Ghugre et al. · Blood · 2005 · 1K citations · Full text

Pathology and genetics: Tumours of haematopoietic and lymphoid tissues

Paresh Vyas · The Lancet Oncology · 2001 · 988 citations

Lymphoid Neoplasia, Cancer Pathology, Hematology +4

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

Maria Domenica Cappellini · Blood · 2005 · 713 citations · Full text

Non-invasive assessment of hepatic iron stores by MRI

Y. Gandon, Damien Olivié, Dominique Guyader et al. · The Lancet · 2004 · 665 citations

Hepatic Iron Stores, Engineering, Hepatology +10